We investigated *Clostridium difficile* in calves and the similarity between bovine and human *C. difficile* PCR ribotypes by conducting a case-control study of calves from 102 dairy farms in Canada. Fecal samples from 144 calves with diarrhea and 134 control calves were cultured for *C. difficile* and tested with an ELISA for *C. difficile* toxins A and B.

*Clostridium difficile* was isolated from 31 of 278 calves: 11 (7.6%) of 144 with diarrhea and 20 (14.9%) of 134 controls (p = 0.009). Toxins were detected in calf feces from 58 (56.8%) of 102 farms, 57 (39.6%) of 144 calves with diarrhea, and 28 (20.9%) of 134 controls (p = 0.0002). PCR ribotyping of 31 isolates showed 8 distinct patterns; 7 have been identified in humans, 2 of which have been associated with outbreaks of severe disease (PCR types 017 and 027).

*Clostridium difficile* may be associated with calf diarrhea, and cattle may be reservoirs of *C. difficile* for humans.
Samples were scored at the farm using a 4-grade fecal scoring system and then stored at 4°C within 6 hours of collection. A score of 1 represented hard, dry fecal matter; score 2, pasty and sticky feces; score 3 soft feces; and score 4, watery feces that would adopt the shape of the container immediately after sampling. Samples with a score of 4 were considered to have diarrhea, whereas scores of 1 and 2 were controls. Samples with a score of 3 were discarded to reduce selection bias. Selected samples were recoded for blinding purposes and stored at −70°C within 24 hours of collection. A questionnaire that requested information about colostrum quality and administration, diet, housing, cleaning and disinfection practices, antimicrobial or antiprotozoal feed supplements, level of nose-to-nose contact among calves, vaccination of dams, and dehorning was administered on each farm to investigate risk factors for C. difficile in feces.

C. difficile Culture and Detection of Toxins A and B

Fecal samples were processed within 2 hours after thawing. Enrichment culture was performed as previously described (7,18). Briefly, =1 g of homogenized fecal matter was mixed with 2 mL of 96% ethanol and agitated at room temperature for 50 minutes to select for bacterial spores. The sediment was recovered after centrifugation at 3,800 × g for 10 minutes and resuspended in 5 mL of cycloserine-cefoxitin fructose broth (C. difficile agar and C. difficile supplement SR0096; Oxoid, Columbia, MD, USA) that was incubated anaerobically at 37°C for 7 days. This broth was treated with 96% ethanol (1:1 vol/vol), centrifuged at 3,800 × g for 10 minutes, and the sediment was resuspended in 200 µL of sterile deionized water. Thereafter, 200 µL of streaked onto cycloserine-cefoxitin fructose agar and blood agar that were incubated anaerobically at 37°C. Plates were evaluated in an anaerobic environment daily for ≤5 days. If present, at least 2 colonies (swarming, flat, rough, non-hemolytic) were subcultured. C. difficile was identified by Gram stain (spore-forming gram-positive rods) and detection of L-proline aminopeptidase activity (Pro Disc, Remel, Lenexa, KS, USA) (19). Isolates were stored at −70°C until molecular analyses were performed.

Feces were screened for C. difficile toxins A and B by using an ELISA (Tox A/B ELISA, TechLab, Blacksburg, VA, USA) (20). The test was performed per manufacturer’s instructions. Two observers interpreted the reactions in a blinded fashion.

Extraction of DNA

DNA was extracted by using a Chelex resin-based kit (InstaGene Matrix, Bio-Rad, Laboratories, Hercules, CA, USA) (21). After centrifugation of the C. difficile DNA–containing solutions, 125 µL of supernatant was collected and stored at −20°C as a template for PCR analyses.

PCR Ribotyping

PCR ribotyping analyses were performed as previously described (22). DNA was amplified by using a thermal cycler (Touchgene Gradient, Techne Inc., Burlington, NJ, USA). Ribotype patterns were compared visually with C. difficile PCR ribotypes from humans and other animals from the provinces of Ontario, Quebec, and Manitoba, Canada. The first isolate identified for each PCR ribotype was submitted to the Anaerobe Reference Laboratory, University Hospital of Wales, Cardiff, United Kingdom, for comparison (23).

Detection of tcdA, tcdB, tcdC, and cdtB Genes

Amplification of nonrepeating and repeating sequences of the tcdA gene and the nonrepeating sequences of the tcdB gene was performed as previously described (24). Identification of tcdC and cdtB genes was based on previous protocols (11,24,25). Reference strains were included as positive and negative controls in every experiment.

Antimicrobial Drug Susceptibility Tests

MICs for metronidazole, clindamycin, levofloxacin, and vancomycin were determined by using the E-test method (AB Biodisk, Solna, Sweden) (26). A McFarland standard 1 suspension of pure C. difficile colonies was placed on Muller-Hinton blood agar plates (Oxoid, Basingstoke, UK). After 48 hours of anaerobic incubation, MICs were determined by consensus of 2 observers.

Toxinotyping of C. difficile Strains

Toxinotyping analysis involved amplification and enzymatic restriction of PCR fragment A3 of tcdA and PCR fragment B1 of tcdB. This was performed following a previously published protocol (27).

Other Enteropathogens

Because intestinal cryptosporidiosis was common (40.6%) in dairy calves <28 days of age in the study area (16), samples examined for C. difficile were also tested for Cryptosporidium spp. oocysts (sucrose wet mount test) to control for potential interactions regarding diarrhea. Other calf enteropathogens were not investigated because they are less prevalent in the region (L.A. Trotz-Williams et al., unpub. data).

Statistical Analysis

Multivariate stepwise logistic regression analyses were performed by using SAS statistical software (SAS Institute, Cary, NC, USA). Associations between farm management data, age, sampling month, and results from
laboratory tests were investigated by using a generalized model procedure (GenMod in SAS). Variables associated with diarrhea and *C. difficile* or its toxins in feces were investigated. During initial model building, variables with p<0.15 were selected to construct final models. Parameters were considered statistically significant if p values were <0.05. A generalized linear mixed model controlling for farm as a random effect was used to estimate and test the farm variance component. Relationships between *C. difficile* toxins and diarrhea and between *C. difficile* toxins and the age and month of sampling were investigated in the models. Pairwise comparisons of least square means were performed, and approximated Tukey adjusted p values were computed. Reported exact p values, odd ratios (ORs), and 95% confidence intervals (CIs) were determined with exact conditional logistic regression tests by using LogXact 5 software (Cytel Inc., Cambridge, MA, USA) when analyses did not yield exact values with SAS software.

**Results**

A total of 278 calves were studied: 144 with diarrhea and 134 controls. The mean age of the sample was 14.2 days (range 5–30 days); 39 calves were 5–7 days of age, 107 were 8–14 days of age, 96 were 15–21 days of age, and 32 were 22–30 days of age. Four calves had no age recorded and were not used for descriptive information regarding age. The mean ages of the control calves (14.8 days, 95% CI 13.7–15.9) and calves with diarrhea (13.9 days, 95% CI 13.0–14.7) were not significantly different (p = 0.16).

*C. difficile* was isolated from 31 (11.2%) of 278 calves from 25 (25%) of 102 farms. This bacterium was more commonly identified in feces from control calves (14.9%, 20/134) than in feces from calves with diarrhea (7.6%, 11/144) (OR 3.47, 95% CI 1.27–10.24, exact 2-tailed p = 0.006). No association was found between administration of feed supplemented with oxytetracycline (33 calves on 11 farms) or anticoccidial drugs (251 calves on 91 farms) and *C. difficile* and its toxins in feces.

*Cryptosporidium* spp. oocysts in feces were significantly associated with diarrhea and identified in 80 (55.9%) of 144 calves with diarrhea and 19 (14.2%) of 134 control calves (OR 8.23, 95% CI 4.35–16.26, exact 2-tailed p<0.0001). However, generalized linear model analysis showed no interaction between *Cryptosporidium* spp. and *C. difficile* toxins (p>0.5) or between *Cryptosporidium* spp. and *C. difficile* culture (p>0.5).

Eight calf PCR ribotypes were identified among 31 *C. difficile* isolates (Figure). Of these, 7 ribotypes represented by 30 (96.7%) isolates were toxigenic (Table 2). Isolates from 5 ribotypes had the classic *tcdC* fragment, and ribotypes A11 and F12 had the major type A deletion (=39 bp deletion) (Table 2). Isolates of ribotype D189 had a *tcdC* fragment, which is indicative of either a type B or C deletion (=18 bp).

The MIC range, MIC$_{50}$, and MIC$_{90}$, and the percentage of resistant *C. difficile* isolates are shown in Table 3. All 30 isolates tested were susceptible to metronidazole and vancomycin. The prevalence of resistance for clindamycin and levofloxacin was similar (73%, 22/30 isolates), but 18 (82%) of the 22 resistant isolates were resistant to both antimicrobial drugs. Calf ribotypes A11 (5/9 isolates), B89 (9/9), C129 (2/2), and D189 (4/4) were overrepresented among the resistant isolates.

<table>
<thead>
<tr>
<th>Pairwise comparison</th>
<th>Odds ratio</th>
<th>95% CI</th>
<th>Adjusted Tukey p values</th>
</tr>
</thead>
<tbody>
<tr>
<td>May vs August†</td>
<td>3.62</td>
<td>1.8–8.3</td>
<td>0.007</td>
</tr>
<tr>
<td>June vs August†</td>
<td>3.17</td>
<td>1.3–7.7</td>
<td>0.029</td>
</tr>
<tr>
<td>July vs August†</td>
<td>2.58</td>
<td>1.2–5.5</td>
<td>0.038</td>
</tr>
<tr>
<td>May vs July</td>
<td>1.41</td>
<td>0.7–2.8</td>
<td>0.59</td>
</tr>
<tr>
<td>June vs July</td>
<td>1.23</td>
<td>0.6–2.6</td>
<td>0.85</td>
</tr>
<tr>
<td>May vs June</td>
<td>1.14</td>
<td>0.5–2.6</td>
<td>0.95</td>
</tr>
</tbody>
</table>

*‡* CI, confidence interval. The number of positive *C. difficile* ELISA test results and calves sampled per month was May, 23/57; June, 16/41; July, 34/105; and August, 12/75. August data include 2 observations from September.

†Statistically significant.
Comparison of the 8 calf PCR ribotypes with a local collection of 25 ribotypes of *C. difficile* isolated from humans showed that 3 calf ribotypes representing 17 (54.8%) of 31 isolates were indistinguishable or similar to ribotypes associated with CDAD in humans in Ontario and Quebec (Figure). Ribotype B89, a strain that produces toxin B but not toxin A, was indistinguishable from a strain obtained from patients during a nosocomial outbreak of CDAD in Manitoba, Canada (Figure) (28). When compared with a collection of canine isolates from southern Ontario (29), this ribotype was also identified in healthy dogs (Figure). Isolates B89 and D89 were not clustered; they were isolated from farms distributed across the studied region with ≈500 km between the most distant ones. Comparison of 7/8 calf ribotypes (representing 30/31 isolates) with a *C. difficile* PCR ribotype library at the Anaerobe Reference Laboratory, University Hospital of Wales, Cardiff, United Kingdom, that contained >160 *C. difficile* ribotypes showed that all bovine ribotypes have been identified in humans (Table 2). Toxinotyping of isolates from calf ribotypes B89/ARL-UK PCR ribotype 017 and D189/ARL-UK PCR type 027 indicated that they were toxinotypes VIII and III, respectively. Other calf ribotypes were not toxinotyped.

### Discussion

This study has demonstrated that shedding of *C. difficile* is common in dairy calves in Ontario regardless whether they have enteric disease. The overall prevalence of shedding (11.2%) was similar to that previously reported (17). However, that shedding of *C. difficile* was more common in control animals was surprising, particularly because 96.7% of the isolates were toxigenic. The reason for this finding is unclear, and natural and methodologic reasons should be considered. Whether the isolation method used in this study resulted in identification bias in favor of 1 of the groups (i.e., control animals) is not known. Pretreatment of fecal samples with ethanol has been shown to facilitate the recovery of *C. difficile* in asymptomatic humans (18). However, how this method would work in calves with and without diarrhea is unknown. The dilutional effect of watery stools could have prevented *C. difficile* from being isolated from calves with diarrhea, or *C. difficile* may not be a primary pathogen in calves. In addition, the concentration of *C. difficile* in the

---

Table 2. *Clostridium difficile* PCR ribotypes and toxin genes of 31 isolates obtained from dairy calves in southern Ontario, Canada, 2004

<table>
<thead>
<tr>
<th>Toxigenic classification†</th>
<th>A-11</th>
<th>B-89</th>
<th>C-129</th>
<th>D-189</th>
<th>E-257</th>
<th>F-12</th>
<th>H-75</th>
<th>I-157</th>
<th>Subtotal, no. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A-B(^<em>) cdtB(^</em>)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>1 (3.2)</td>
</tr>
<tr>
<td>A-B(^<em>) cdtB(^</em>)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>2</td>
<td>–</td>
<td>–</td>
<td>2 (6.5)</td>
</tr>
<tr>
<td>A-B(^<em>) cdtB(^</em>)</td>
<td>–</td>
<td>–</td>
<td>2</td>
<td>–</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>–</td>
<td>8 (25.8)</td>
</tr>
<tr>
<td>A-B(^<em>) cdtB(^</em>)</td>
<td>7</td>
<td>–</td>
<td>–</td>
<td>4</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>11 (35.5)</td>
</tr>
<tr>
<td>A-B(^<em>) cdtB(^</em>)</td>
<td>–</td>
<td>8</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>8 (25.8)</td>
</tr>
<tr>
<td>A-B(^<em>) cdtB(^</em>)</td>
<td>–</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1 (3.2)</td>
</tr>
<tr>
<td>Subtotal, no. (%)</td>
<td>7 (22.6)</td>
<td>9 (29)</td>
<td>2 (6.5)</td>
<td>4 (12.9)</td>
<td>4 (12.9)</td>
<td>3 (9.7)</td>
<td>1 (3.2)</td>
<td>1 (3.2)</td>
<td>31 (100)</td>
</tr>
<tr>
<td>Type of tcdC deletion‡, (no.)</td>
<td>A (7)</td>
<td>None (9)</td>
<td>None (2)</td>
<td>B (4)</td>
<td>None (4)</td>
<td>A (3)</td>
<td>None (1)</td>
<td>None (1)</td>
<td></td>
</tr>
<tr>
<td>Human PCR ribotypes§</td>
<td>078</td>
<td>017</td>
<td>077</td>
<td>027</td>
<td>014</td>
<td>033</td>
<td>078</td>
<td>NS</td>
<td></td>
</tr>
</tbody>
</table>

†By PCR typing method of Bidet et al. (22).
‡A, toxic gene tcdA; B, tcdB; –, absence or presence of the categorized gene; cdtB, gene that codifies CDTb, the binding segment of the binary toxin.
§By PCR typing method of Deacon et al. (23).

NS, not submitted for analysis.
Table 3. MIC\(_{50}\) and MIC\(_{90}\) range and resistance frequencies of 30 bovine \textit{Clostridium difficile} isolates to 4 antimicrobial drugs by E-test on Muller-Hinton agar after 48 h of incubation*

<table>
<thead>
<tr>
<th>Drug</th>
<th>MIC(_{50}), (\mu)g/mL</th>
<th>MIC(_{90}), (\mu)g/mL</th>
<th>Range, (\mu)g/mL</th>
<th>Resistant isolates, % (no. resistant/no. tested), MIC ((\mu)g/mL)</th>
<th>Overrepresented PCR ribotypes (no.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vancomycin</td>
<td>0.5</td>
<td>0.75</td>
<td>0.25–1.5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>0.38</td>
<td>0.75</td>
<td>0.125–2.0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>32</td>
<td>32</td>
<td>4 to &gt;32</td>
<td>73 (22/30), &gt;32</td>
<td>B89 (9/9), C129 (2/2), D189 (4/4), other 3 ribotypes (7 isolates)</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>16.0</td>
<td>&gt;256</td>
<td>6 to &gt;256</td>
<td>73 (22/30), &gt;12; 37 (11/30), &gt;256</td>
<td>B89 (9/9), C129 (2/2)</td>
</tr>
</tbody>
</table>

*The breakpoints used were vancomycin susceptible, <4.0 \(\mu\)g/mL; vancomycin resistant, >32.0 \(\mu\)g/mL; metronidazole susceptible, <8.0 \(\mu\)g/mL; metronidazole resistant, >32.0 \(\mu\)g/mL; clindamycin susceptible, <2.0 \(\mu\)g/mL; clindamycin resistant >8.0 \(\mu\)g/mL; levofloxacin susceptible, <2.0 \(\mu\)g/mL; levofloxacin resistant, >8.0 \(\mu\)g/mL.

intestinal tract may not correlate with the concentration of spores in feces. Since quantitative culture was not performed in this study, conclusions cannot be made.

The pathophysiology and epidemiology of \textit{C. difficile} are not completely understood in humans, and some studies have reported that asymptomatic colonization with \textit{C. difficile} may have a protective effect against CDAD (30). In humans, 50%–80% of asymptomatic infants may be colonized with toxigenic \textit{C. difficile} and have its toxins in their feces (31). \textit{C. difficile} has been reported to affect neonatal foals and piglets (7,8).

Detection of toxins A and B in feces of humans with diarrhea is considered diagnostic for CDAD (31,32). The positive association between fecal \textit{C. difficile} toxins and calf diarrhea found in our study indicates that \textit{C. difficile} might be a pathogen in calves. However, the clinical relevance of this association is uncertain because it is based on the assumption that the ELISA used has acceptable sensitivity and specificity in calves. The validity of this ELISA has not been reported for most animal species, including cattle. For humans and pigs, adequate sensitivities and specificities for this ELISA (65%–95% and 95%–100%, respectively) (20,32,33) contrast with recently reported suboptimal performance for canine feces (34). With an apparent interspecies variability of the ELISA, validation of this test for bovine feces is required before conclusions regarding causal associations can be made.

The finding that calves were more likely to have detectable levels of \textit{C. difficile} toxins in their feces early in life is consistent with findings of a previous study (17). The reason for this is unclear, although \textit{C. difficile} may be better able to colonize, proliferate, and produce toxins in younger animals with less developed intestinal microflora. In other animal species and humans, administration of antimicrobial drugs is considered a predisposing factor for development of CDAD (3,7,35,36). No statistical associations were identified in this regard at the calf level because questionnaires were designed to explore farm practices.

Molecular analyses showed that a relevant proportion of the \textit{C. difficile} isolates (9/31) had \textit{tcdB} genes but not \textit{tcdA} genes (A–B\(^{-}\)). These variant isolates are uncommon in humans but have been reported in association with outbreaks of CDAD (2,36). In a previous study in calves, no A–B\(^{-}\) isolates were identified (17). This discrepancy could be due to potential differences between the 2 study populations.

In our study, the 9 calf A–B\(^{-}\) isolates and a control strain were classified as ribotype pattern B89 type 017 (Figure). This ribotype has been reported in outbreaks of CDAD in humans in various countries (2,28,36), including the Canadian provinces of Ontario, Quebec, and Manitoba, from which the human control strain was obtained (28). Toxinotyping (type VIII) and \textit{tdcC} analysis (classic gene) of these 9 calf isolates supported their similarity to human strains. The epidemiologic explanation for the presence of this human epidemic strain in calves and in healthy dogs (29) is uncertain, but this finding raises the concern of potential animal-to-human transmission and vice versa. No isolates of bovine origin were available for additional retrospective comparisons.

The second major calf ribotype common to humans in Ontario and Quebec was D189/PCR ribotype 027 (positive for \textit{tcdA}, \textit{tcdB} and \textit{cdtB}, type B \textit{tcdC} deletion, and toxino-type III). Molecular characteristics of this ribotype indicate that it is a hypertoxin-producing ribotype recently reported as a cause of serious outbreaks of disease in humans in North America and Europe (1). In Quebec, Canada, \textit{C. difficile} type 027 was isolated during an outbreak from 67% of persons with hospital-acquired CDAD and 37% of persons with community-acquired CDAD (1). The pathogenicity of this ribotype is believed to be associated with a high production of toxins A and B in vitro, and with fluoroquinolone resistance (3,4).

The 4 calf isolates of PCR D189/ribotype 027 identified in our study were not geographically clustered. This result and the recent finding of this strain in a dog in Ontario indicate that this \textit{C. difficile} ribotype may be widely disseminated in the community in different animal species (37). The public health consequences of this are unclear and require further study. Whether cattle could play a role in dissemination of this strain through direct contact, environmental contamination, or the food chain should be determined. Although \textit{C. difficile} is not considered a foodborne pathogen, it has been identified in raw meat intended for pet
consumption (38) and in retail meat from grocery stores in Ontario (A. Rodríguez-Palacios et al., unpub. data).

Results of antimicrobial drug susceptibility tests for metronidazole, vancomycin, and clindamycin are consistent with those of previous reports in humans, in which antimicrobial susceptibility of *Clostridium difficile* strains to metronidazole and vancomycin was $\approx 100\%$ and antimicrobial resistance to clindamycin was $\approx 70\%–80\%$ (2,26,35). Most isolates (73%) were resistant to levofloxacin, which is not administered to cattle. Antimicrobial drug resistance to fluoroquinolones has been described in *C. difficile* PCR ribotype 027 as a major risk factor for development of CDAD (4,5). The development of fluoroquinolone resistance in human-derived strains has been hypothesized to result from increased use of these antimicrobial drugs, which has also been associated with a higher risk for CDAD in hospitals (3,5).

Use of fluoroquinolones was not voluntarily reported for any of the farms or calves in this study, and levofloxacin resistance cannot be extrapolated to other fluoroquinolones (39). In Canada, fluoroquinolones are not approved for use in dairy cattle or veal calves. Fluoroquinolones have not been approved for veterinary use in any food-producing animals in Canada until recently, when a commercial enrofloxacin product was approved only for use in beef cattle with unresponsive respiratory disease (39). As part of a Canadian surveillance program, Health Canada, through the Canadian Integrated Program for Antimicrobial Resistance Surveillance, has monitored fluoroquinolone resistance in strains of *Escherichia coli* and *Salmonella* spp. from beef cattle since 2001–2002. According to the Canadian Integrated Program for Antimicrobial Resistance Surveillance 2002 and 2003 reports, no resistance to fluoroquinolones has been observed (40). Thus, the source of fluoroquinolone resistance in calf-derived *C. difficile* isolates in our study is uncertain and is not substantiated on the hypothesis of excessive use of fluoroquinolones, i.e., enrofloxacin, in cattle. Whether this resistance has any epidemiologic association with companion animals (i.e., dogs) or humans for which fluoroquinolones have been approved for many years remains unknown.

The results of our study indicate that *C. difficile* may play a role in neonatal calf diarrhea, which is a serious concern in the bovine industry. Calf *C. difficile* isolates that are indistinguishable from human strains and have fluoroquinolone resistance and *tcdC* deletions also raise the possibility of interspecies transmission. Although this study did not confirm that infection with *C. difficile* is zoonotically transmitted, further study is indicated to evaluate this possibility. Investigations of recent changes in the epidemiology of CDAD and identification of new pathogenic genotypes should also involve concurrent evaluation of animal reservoirs or origins. Validation studies are also required to assess culture protocols and immunomodulatory tests for identification of *C. difficile* and its toxins in cattle feces.

**Acknowledgments**

We thank William Sears for statistical support; Joyce Rousseau and Hayley Martin for laboratory technical assistance; Erin Vernooy, Nicole Perkins, and Jennifer Wilstra for assistance in collection of samples; and Michelle J. Alfa for providing an isolate from the CDAD outbreak in Manitoba, Canada. Preliminary results of this investigation were presented at the annual forum of the American College of Veterinary Internal Medicine, Baltimore, Maryland, USA, June 2005.

This study was supported by the Ontario Ministry of Agriculture and Food, Ottawa, Ontario, Canada.

Dr Rodríguez-Palacios recently completed a doctorate degree in veterinary sciences and a residency in large animal internal medicine at the Ontario Veterinary College, University of Guelph. His research interests include development of probiotics for prevention of diarrhea and the epidemiology of infectious diseases of large animals, particularly of pathogens with potential public health implications.

**References**


